Evidence map›Paper›PMID 34354699›Full record

ArticleFrontiers in immunology2021

Potential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients.

Helen Ferreira, Mayara Abud Mendes, Mayara Garcia de Mattos Barbosa, Eliane Barbosa de Oliveira, Anna Maria Sales, Milton Ozório Moraes, Euzenir Nunes Sarno, Roberta Olmo Pinheiro

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Frontiers in microbiology · 2023
    Article
  4. Interplay among differential exposure toFrontiers in immunology · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Helen FerreiraLeprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Mayara Abud MendesLeprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Mayara Garcia de Mattos BarbosaCascalho-Platt Laboratory, Department of Surgery, University of Michigan, Ann Arbor, MI, United States.
Eliane Barbosa de OliveiraLeprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Anna Maria SalesLeprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Milton Ozório MoraesLeprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Euzenir Nunes SarnoLeprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Roberta Olmo PinheiroLeprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Fundação Oswaldo Cruz · BRUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of multibacillary cases of leprosy with multidrug therapy (MDT) comprises 12 doses of a combination of rifampicin, dapsone and clofazimine. Previous studies have described the immunological phenotypic pattern in skin lesions in multibacillary patients. Here, we evaluated the effect of MDT on skin cell phenotype and on the

Indexed as

AdolescentAdultAgedAged, 80 and overBacterial LoadBiomarkersChemokine CXCL10Drug Therapy, CombinationFemaleHumansLeprostatic AgentsLeprosyMaleMiddle AgedMycobacterium lepraeSkinBiomarkersChemokine CXCL10CXCL10 protein, humanLeprostatic AgentsCXCL-10IFN-γleprosymultidrug therapyskin cells

Identifiers

PMID34354699
PMCPMC8329534
OpenAlexW3189146129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.